Balchem Corporation develops, manufactures, and markets specialty ingredients and performance products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally. The company is headquartered in New Hampton, New York.
133 articles
Balchem Corporation is deemed a high-quality specialty ingredients firm with strong financial health, though analysts warn its current valuation is full relative to market averages. Investors are advi
Balchem Corporation shares trade below intrinsic value following a 47% rally, backed by record sales, a new $650 million credit facility, and share buybacks per DCF analysis.
Balchem Corporation highlights five bakery market trends via a BakeShure infographic, emphasizing healthier consumer preferences and the use of encapsulated active ingredients for product innovation.
Balchem Corporation reported strong third-quarter 2026 sales and net income, supported by a share repurchase boosting EPS. Analysts forecast continued revenue growth through 2029, though capacity and
Balchem Corporation reported strong third-quarter 2026 results, with revenue reaching $290.66 million, an 8.6% increase year-over-year. All three segments showed sales growth driven by market factors
TradingView provides an overview of Balchem Corporation's financials and analyst estimates, including income statements and valuation metrics. Users are advised to conduct independent research as the
Balchem Corporation reported record third-quarter 2026 results with net sales up 8.6% to $290.7 million and adjusted EPS of $1.57, supported by growth across Human Nutrition, Animal Nutrition, and Spe
Balchem Corporation reported Q3 2026 financial results that met Wall Street expectations, with revenue rising 8.6% year-over-year to $290.7 million, driven by growth in its Human Nutrition and Health
A financial data platform provides analyst estimates and historical performance metrics for Balchem Corp (BCPC) listed on the Mexican Stock Exchange. Users can compare actual results against forecasts
Balchem Corporation reported an 8.6% year-over-year increase in third-quarter net sales to $290.7 million, driven by growth across its Human Nutrition, Animal Nutrition, and Specialty Products segment
Balchem Corporation reported record Q3 2026 net sales of $270.8 million, a 16.7% increase year-over-year, driven by strong performance in nutrition segments and acquisitions.
Balchem Corporation reported record third-quarter 2026 financial results, with net sales increasing 8.6% year-over-year to $290.7 million. GAAP net earnings rose 16.0% to $46.7 million, supported by g
Financial data from ICE Data Services reports Balchem Corp's pretax income on the Hannover Stock Exchange. The company trades under ticker BL9B, though the market is currently closed with no active tr
Balchem Corp (HAN:BL9B) financial data regarding total non-operating income is presented on the Hannover Stock Exchange, sourced from ICE Data Services and FactSet.
Balchem Corporation reported a minority interest of MXN0.00 million as of June 2026, with a GF Score of 93/100 and two identified investor warning signs.
Balchem Corporation reported current deferred revenue of MXN0.00 million as of June 2026. The article provides historical data and definitions regarding this financial metric sourced from GuruFocus.
Balchem Corporation scheduled a conference call for October 23, 2026, to discuss third-quarter financial results. CEO Ted Harris and CFO Martin Bengtsson will host the event, with financial data relea
Balchem Corporation will showcase its branded ingredients and scientific leadership at SupplySide Global 2026, highlighting new research on health-focused compounds and GLP-1 companion products for fo
Balchem Corporation, a specialty chemicals firm in human and animal nutrition, releases updated financial metrics and analyst insights. The report details stock performance relative to the S&P 500 alo
Balchem published a whitepaper exploring DNA methylation's role in cellular health throughout life. The paper identifies nutrient gaps and highlights the growing market for methyl-donating ingredients
Balchem Corp disclosed its cash flow from investing activities on the Hannover Stock Exchange. Market data indicates the trading platform currently shows no active trades.
Balchem Corp (HAN:BL9B) operating cash flow data is listed on the Hannover Stock Exchange, where the market is currently closed with no trades recorded. Data is supplied by ICE Data Services and FactS
Balchem Corporation reported total revenue of 883.06 million EUR last year, with its Human Nutrition and Health segment leading performance. The United States served as the primary regional market, co
Balchem Corporation disclosed net income before discontinued operations, tracked under the Hannover Stock Exchange symbol BL9B. The report details financial metrics including value and change over spe
Balchem Corporation's SVP and Chief R&D Officer Ren Anthony Gonzalez disclosed share holdings, revealing that most direct shares are restricted stock vesting over one to three years.
Argus Research raised its price target for Balchem Corporation to $185.00 from $167.84, noting the company's development of specialty performance ingredients for various industries.
A Discounted Cash Flow analysis indicates Balchem Corporation is undervalued by roughly 25%, supported by $177.6 million in trailing twelve-month free cash flow. Capacity expansion offers upside, thou
Balchem announced research from the University of Arkansas showing Optifolin+ significantly enhances cellular DNA methylation and SAM levels. These findings support the ingredient's role in epigenetic
Balchem Corporation announced that key executives, including CEO Ted Harris, will attend the 9th Annual Wells Fargo Consumer Conference on September 23, 2026. The company specializes in developing and
Balchem Corp reported 18.70 billion MXN in annual revenue, with its Human Nutrition and Health segment contributing the majority at 11.89 billion MXN. The United States was the top regional market, ge
ChemBrief